The stock has now broken below S-1 support at $2.92, confirmed by a large red candle signaling a clear downside breakout. With small-cap biotech under heavy pressure, a move toward S-2 support at $1.84 (dating back to Oct. 2023) is now a real possibility.
Not trying to pick on the stock — just calling what’s in front of us. I’ve held off buying so far, and looking back, that patience is paying off. Still watching for a better entry. Stay tuned.
Not trying to pick on the stock — just calling what’s in front of us. I’ve held off buying so far, and looking back, that patience is paying off. Still watching for a better entry. Stay tuned.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.